Ron Bentsur - Net Worth and Insider Trading

Ron Bentsur Net Worth

The estimated net worth of Ron Bentsur is at least $19 Million dollars as of 2024-12-03. Ron Bentsur is the Chairman & CEO, 10% Owner of Nuvectis Pharma Inc and owns about 3,266,424 shares of Nuvectis Pharma Inc (NVCT) stock worth over $16 Million. Ron Bentsur is the CEO of Keryx Biopharmaceuticals Inc and owns about 777,209 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $3 Million. Ron Bentsur is also the Director of Stemline Therapeutics Inc and owns about 7,285 shares of Stemline Therapeutics Inc (STML) stock worth over $86,182. Besides these, Ron Bentsur also holds Beyond Air Inc (XAIR) . Details can be seen in Ron Bentsur's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ron Bentsur has not made any transactions after 2024-11-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Ron Bentsur

To

Ron Bentsur Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ron Bentsur owns 6 companies in total, including Beyond Air Inc (XAIR) , Stemline Therapeutics Inc (STML) , and UroGen Pharma Ltd (URGN) among others .

Click here to see the complete history of Ron Bentsur’s form 4 insider trades.

Insider Ownership Summary of Ron Bentsur

Ticker Comapny Transaction Date Type of Owner
XAIR Beyond Air Inc 2023-03-20 director
STML Stemline Therapeutics Inc 2020-06-10 director
URGN UroGen Pharma Ltd 2019-01-01 director & Chief Executive Officer
LIMIT LIMIT 2015-04-06 director & Chief Executive Officer
LIMIT LIMIT 2006-08-17 CEO
LIMIT LIMIT 2024-11-15 director & Chairman & CEO

Ron Bentsur Latest Holdings Summary

Ron Bentsur currently owns a total of 4 stocks. Among these stocks, Ron Bentsur owns 3,266,424 shares of Nuvectis Pharma Inc (NVCT) as of November 15, 2024, with a value of $16 Million and a weighting of 85.29%. Ron Bentsur owns 777,209 shares of Keryx Biopharmaceuticals Inc (KERX) as of April 6, 2015, with a value of $3 Million and a weighting of 13.86%. Ron Bentsur also owns 7,285 shares of Stemline Therapeutics Inc (STML) as of March 18, 2015, with a value of $86,182 and a weighting of 0.46%. The other 1 stocks Beyond Air Inc (XAIR) have a combined weighting of 0.39% among all his current holdings.

Latest Holdings of Ron Bentsur

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NVCT Nuvectis Pharma Inc 2024-11-15 3,266,424 4.92 16,070,806
KERX Keryx Biopharmaceuticals Inc 2015-04-06 777,209 3.36 2,611,422
STML Stemline Therapeutics Inc 2015-03-18 7,285 11.83 86,182
XAIR Beyond Air Inc 2023-03-20 144,736 0.51 73,410

Holding Weightings of Ron Bentsur


Ron Bentsur Form 4 Trading Tracker

According to the SEC Form 4 filings, Ron Bentsur has made a total of 42 transactions in Nuvectis Pharma Inc (NVCT) over the past 5 years, including 42 buys and 0 sells. The most-recent trade in Nuvectis Pharma Inc is the acquisition of 20,000 shares on November 15, 2024, which cost Ron Bentsur around $98,400.

According to the SEC Form 4 filings, Ron Bentsur has made a total of 0 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 1,592 shares on April 6, 2015, which brought Ron Bentsur around $18,595.

According to the SEC Form 4 filings, Ron Bentsur has made a total of 0 transactions in Stemline Therapeutics Inc (STML) over the past 5 years. The most-recent trade in Stemline Therapeutics Inc is the sale of 1,388 shares on March 18, 2015, which brought Ron Bentsur around $22,375.

More details on Ron Bentsur's insider transactions can be found in the Insider Trading History of Ron Bentsur table.

Insider Trading History of Ron Bentsur

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ron Bentsur Trading Performance

GuruFocus tracks the stock performance after each of Ron Bentsur's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ron Bentsur is 17.72%. GuruFocus also compares Ron Bentsur's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ron Bentsur within 3 months outperforms 16 times out of 46 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ron Bentsur's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ron Bentsur

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
22 out of 43 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 2.35 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 2.34 LIMIT LIMIT LIMIT LIMIT LIMIT

Ron Bentsur Ownership Network

Ownership Network List of Ron Bentsur

No Data

Ownership Network Relation of Ron Bentsur

Insider Network Chart

Ron Bentsur Owned Company Details

What does Beyond Air Inc do?

Who are the key executives at Beyond Air Inc?

Ron Bentsur is the director of Beyond Air Inc. Other key executives at Beyond Air Inc include director & President & CEO Amir Avniel , Chief Medical Officer Jeff Lynn Myers , and Chief Operating Officer Michael A. Gaul .

Beyond Air Inc (XAIR) Insider Trades Summary

Over the past 18 months, Ron Bentsur made no insider transaction in Beyond Air Inc (XAIR). Other recent insider transactions involving Beyond Air Inc (XAIR) include a net purchase of 3,115,290 shares made by Robert Carey , a net purchase of 1,704,401 shares made by Steven A. Lisi , and a net purchase of 39,266 shares made by Erick Lucera .

In summary, during the past 3 months, insiders sold 0 shares of Beyond Air Inc (XAIR) in total and bought 2,953,252 shares, with a net purchase of 2,953,252 shares. During the past 18 months, 28,423 shares of Beyond Air Inc (XAIR) were sold and 4,868,957 shares were bought by its insiders, resulting in a net purchase of 4,840,534 shares.

Beyond Air Inc (XAIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Beyond Air Inc Insider Transactions

No Available Data

Ron Bentsur Mailing Address

Above is the net worth, insider trading, and ownership report for Ron Bentsur. You might contact Ron Bentsur via mailing address: 750 Lexington Ave, 20th Fl, New York Ny 10022.

Discussions on Ron Bentsur

No discussions yet.